Results 31 to 40 of about 811,174 (190)
A Fast and Clean BTK Inhibitor [PDF]
Abstract Bruton’s tyrosine kinase (BTK) is a major drug target for B-cell related malignancies; however, existing BTK inhibitors approved for cancer treatment have significant off-targets that limit their use for autoimmune and inflammatory diseases.
Ronen Gabizon, Nir London
openaire +2 more sources
Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors
Bruton tyrosine kinase (BTK) is linked to multiple signalling pathways that regulate cellular survival, activation, and proliferation. A covalent BTK inhibitor has shown favourable outcomes for treating B cell malignant leukaemia.
Min Li (12799) +10 more
core +1 more source
Btk/Itk Dual Inhibitors: Modulating Immunopathology And Lymphopenia For Covid-19 Therapy [PDF]
Bruton\u27s tyrosine kinase (BTK) signaling is involved in innate immune responses and regulates the production of proinflammatory cytokines that can contribute to COVID-19 immunopathology.
McGee, M C +5 more
core +1 more source
Bruton’s tyrosine kinase (BTK) is an attractive therapeutic target in the treatment of cancer, inflammation, and autoimmune diseases. Covalent and noncovalent BTK inhibitors have been developed, among which covalent BTK inhibitors have shown great ...
Honglin Li (19441) +16 more
core +3 more sources
The potential of pirtobrutinib in multiple B-cell malignancies
Bruton’s tyrosine kinase (BTK) is a critical downstream signaling element from the B-cell receptor (BCR) that has been effectively inhibited in B-cell cancers by irreversible, covalent inhibitors including ibrutinib and acalabrutinib.
Jeffrey L. Jensen +4 more
doaj +1 more source
Bruton’s tyrosine kinase (BTK) is a key protein from the TEC family and is involved in B-cell lymphoma occurrence and development. Targeting BTK is therefore an effective strategy for B-cell lymphoma treatment.
Xiangfan Yu +4 more
doaj +1 more source
Frédérique St-Pierre,1 Shuo Ma1,2 1Department of Medicine, Division of Hematology/Oncology and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA; 2Department of Medicine, Division of Hematology/Oncology, Feinberg ...
St-Pierre F, Ma S
doaj
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies
The approval of BTK and PI3K inhibitors (ibrutinib, idelalisib) represents a revolution in the therapy of B cell malignancies such as chronic lymphocytic leukemia (CLL), mantle-cell lymphoma (MCL), diffuse large B cell lymphoma (DLBCL), follicular ...
Laura Ondrisova +3 more
doaj +1 more source
Observations on the use of Bruton’s tyrosine kinase inhibitors in SAR-CoV-2 and cancer
Bruton’s tyrosine kinase (BTK) inhibitors, drugs utilized in cancer, are being repurposed for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) (COVID-19). Recently, BTK inhibitors acalabrutinib and ibrutinib have been found to protect against
Brooke Benner, William E. Carson
doaj +1 more source
The present work reports the microstructural, mechanical, and texture evolution of a dissimilar combination laser‐welded maraging steel with 4340 steel. This is important for aerospace applications. The demand for dissimilar welding is growing rapidly with the requirement of efficient and durable joints.
Bharat Behl +3 more
wiley +1 more source

